Table 4. Prognostic value of the variables in univariate and multivariate analysis.
| Variable | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | |
| Age (yr) | ||||||
| Overall | - | - | 0.439 | - | - | - |
| < 45 vs. ≥ 45, < 60 | 1.362 | 0.375–4.954 | 0.639 | - | - | - |
| < 45 vs. ≥ 60 | 1.884 | 0.575–6.170 | 0.295 | - | - | - |
| Menstruation | ||||||
| Pre vs. post | 0.970 | 0.532–1.770 | 0.921 | - | - | - |
| Tumor size (cm) | ||||||
| Overall | - | - | 0.299 | - | - | - |
| ≤ 2 vs. > 2, ≤ 5 | 0.895 | 0.394–2.034 | 0.792 | - | - | - |
| ≤ 2 vs. > 5 | 0.571 | 0.244–1.336 | 0.196 | - | - | - |
| Histological grade | ||||||
| I, II vs. III | 1.789 | 0.947–3.378 | 0.730 | - | - | - |
| Nodal status | ||||||
| Positive vs. negative | 2.882 | 1.475–5.631 | 0.001 | 2.666 | 1.271–5.594 | 0.010 |
| Ki-67 (%) | ||||||
| ≤ 14 vs. > 15 | 1.013 | 1.002–1.024 | 0.023 | 1.007 | 0.995–1.019 | 0.249 |
| LAG-3 | ||||||
| High vs. low | 1.785 | 0.978–3.258 | 0.059 | - | - | - |
| PD-1 | ||||||
| High vs. low | 1.750 | 0.944–3.244 | 0.076 | - | - | - |
| CD8+TILs | ||||||
| High vs. low | 0.331 | 0.173–0.633 | 0.001 | 0.313 | 0.139–0.705 | 0.005 |
| PD-L1 | ||||||
| High vs. low | 1.421 | 0.781–2.586 | 0.249 | - | - | - |
| LAG-3*PD-1 | ||||||
| LAG-3-high/PD-1-high vs. non-LAG-3-high/PD-1-high | 2.450 | 1.257–4.774 | 0.008 | 1.248 | 0.464–3.353 | 0.661 |
| LAG-3*CD8+TILs | ||||||
| LAG-3-high/CD8+TILs-low vs. non-LAG-3-high/CD8+TILs-low | 3.947 | 2.038–7.644 | < 0.001 | 1.149 | 0.439–3.006 | 0.777 |
| LAG-3*PD-L1 | ||||||
| LAG-3-high/PD-L1-high vs. non-LAG-3-high/PD-L1-high | 3.198 | 1.681–6.087 | < 0.001 | 2.829 | 1.050–7.623 | 0.040 |
HR=hazard ratio; CI=confidence interval; LAG-3=lymphocyte-activation gene-3; PD-1=programmed death-1; TILs=tumor-infiltrating lymphocytes; PD-L1=programmed death ligand-1.
*Interaction.